- Abstract Number: 1583
Race and Disease Severity Predict Reduced Response to Treat-to-Target Urate Lowering Therapy in Gout: Post-hoc Analysis of a Multicenter, Randomized, Double-Blind, Non-Inferiority Trial
- Abstract Number: 0131
Racial Differences in Bone Health of Sarcoidosis Patients: A Retrospective Study
- Abstract Number: 1100
Racial Differences in Clinical Trial Perceptions Among a Large, Predominantly Black Cohort of Patients with Systemic Lupus Erythematosus in the Southeastern United States
- Abstract Number: 0116
Racial Differences in Medication Beliefs and Barriers to Taking Medications Among Patients with SLE
- Abstract Number: 1861
Racial Disparities in Diagnosis and Treatment of Patients with Dermatomyositis of Different Skin Tones
- Abstract Number: 0728
Racial Disparities in Pain: Severity, Interference with Function, and Response to Guided Imagery
- Abstract Number: 0843
Racial Disparities in Patient Satisfaction Following Total Joint Arthroplasty: A Contemporary Trends Analysis from 2013-2021
- Abstract Number: 0089
Racial Disparities in Rheumatology Clinical Trials
- Abstract Number: 1935
Racial Disparities Influence Healthcare Utilization in Pediatric Rheumatology Clinic
- Abstract Number: 0299
Radiographic Change in Patients with Rheumatoid Arthritis and Estimated Baseline Yearly Progression ≥5 or < 5: Post Hoc Analysis of Two Phase 3 Trials of Filgotinib
- Abstract Number: 1898
Radiographic Osteoarthritis Progression Can Be Predicted via Pyrosequencing Analysis of Baseline Peripheral Blood
- Abstract Number: 1804
Raman Spectroscopy Integrated with Polarized Light Microscopy for Diagnosis of Crystallopathies
- Abstract Number: 2237
Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Idiopathic Inflammatory Myopathy: Results of the 24-Week Double-Blind and 28-Week Open-Label Periods
- Abstract Number: 0974
Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneous Lupus Erythematosus Parallels Discrete Changes in Transcriptomic and Cellular Biomarkers
- Abstract Number: 1552
Rare Variant Analysis of Aortopathy Genes in Takayasu’s Arteritis
- Abstract Number: 1924
Reading the Waves: Identifying Distinct Phenotypes of Multisystem Inflammatory Syndrome in Children During the 2020-2021 COVID-19 Pandemic
- Abstract Number: 0243
Real World Evidence of Treatment Effectiveness and Unfavorable Clinical Events for Elderly-onset Early Rheumatoid Arthritis in Japan: Results from the IORRA Study
- Abstract Number: 0418
Real World Evidence on Disease Activity in Patients with Ankylosing Spondylitis Treated with Tumour Necrosis Factor Inhibitors and/or Nonsteroidal Anti-Inflammatory Drugs in Routine Care
- Abstract Number: 0076
Real World Rheumatology Practice of Biologic Monotherapy for the Treatment of Patients with Rheumatoid Arthritis: A Four-year Cohort Study Using a National Claims Database
- Abstract Number: 0289
Real-world Data of Tofacitinib versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients with Rheumatoid Arthritis from a Drug-based Registry
- Abstract Number: 0740
Real-World Demographics, Clinical Characteristics, and Treatment Patterns of Patients Treated with Emapalumab for Secondary Hemophagocytic Lymphohistiocytosis in the United States: The REAL-HLH Study
- Abstract Number: 1374
Real-World Effectiveness and Steroid Sparing Effect of Belimumab in Pediatric Lupus: A Single Center Retrospective Study
- Abstract Number: 0347
Real-World Effectiveness of Belimumab in Patients with SLE in the United States
- Abstract Number: 0201
Real-World Evidence from Social Media Provides Insights into Patient Mental Health Outcomes in the Management of Gout
- Abstract Number: 2138
Real-world Persistence and Treatment Patterns in Psoriatic Arthritis Patients Treated with Anti-IL17 Therapy
- Abstract Number: 0714
Real-World Treatment Effectiveness of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis
- Abstract Number: 1838
Real-World Treatment Patterns Among Adult Patients with Dermatomyositis in the United States
- Abstract Number: 0075
Real-World Treatment Patterns Among Patients with Connective Tissue Disorder–Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based Analysis
- Abstract Number: 0074
Real-World Treatment Patterns, Healthcare Resource Utilization (HCRU) and Costs in Patients with Systemic Lupus Erythematosus (SLE) in the US
- Abstract Number: 0274
Real-world Utilisation and Switching Between Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis in the Australian OPAL Dataset
- Abstract Number: 1387
Real-World Utilization of Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis in Europe
- Abstract Number: 0264
Reasons for Early Discontinuation of Targeted Synthetic (ts) or Biologic (b) DMARDs; Chart Review of 20,343 Drug Episodes Given to Patients with Rheumatoid Arthritis
- Abstract Number: 0897
Reasons for Multiple Biologic DMARD Switching and Characteristics of “Extreme Treatment Nonresponders” in Rheumatoid Arthritis
- Abstract Number: 0427
Recapture Rates with Ixekizumab After Withdrawal of Therapy in Patients with Axial Spondyloarthritis: Results at Week 104 from a Randomized Placebo-controlled Withdrawal Study
- Abstract Number: 0525
Recovery of Renal Function Among ANCA-Associated Vasculitis Patients with Baseline eGFR ≤20 in the Avacopan ADVOCATE Trial
- Abstract Number: 2220
Recurrence of Herpes Zoster Reactivation After Events of Herpes Zoster in Patients Receiving JAK Inhibitors in South Korea: A Nationwide Population-based Study
- Abstract Number: 2268
Recurrent Thrombosis Risk in Non-anticoagulated Antiphospholipid Syndrome Patients: A Prospective Case-Control Study from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
- Abstract Number: 0020
Redoxosomes Mediate a Feed-forward Loop of Cartilage Matrix Destruction Through α5β1 Integrin Signaling in Response to a Fibronectin Matrikine
- Abstract Number: 0701
Reduced Humoral but Maintained Cellular Immune Response to a 3rd COVID-19 Vaccination in Patients with Immune-Mediated Inflammatory Diseases as Compared to Healthy Controls over a 3-months Observational Period
- Abstract Number: 0637
Reduced IgG Sialic Acid Content: A Distinctive Characteristic of Symptomatic Anti-Nuclear Antibodies Positive Individuals
- Abstract Number: 1236
Reduced Inflammation Following 4-weeks TNF-α Inhibitor Treatment Restore Aberrant Cerebral Pain Processing in Rheumatoid Arthritis Patients: A Randomized Double-Blind Placebo-Controlled fMRI Study
- Abstract Number: 2215
Reducing Cardiovascular Risk with Immunomodulators: A Single Blind Randomized Active Comparator Trial Among Patients with Rheumatoid Arthritis
- Abstract Number: 1807
Reduction in Monosodium Urate Crystal Deposit Volume During the MIRROR RCT Trial in Patients Treated with Pegloticase Plus Methotrexate Co-therapy: A Serial Dual-Energy Computed Tomography (DECT) Analysis
- Abstract Number: 2251
Reduction in Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk in Patients Treated with Tofacitinib
- Abstract Number: 0307
Reduction in Structural Damage Progression and Improvement in Clinical Response with Abatacept Treatment in Patients with ACPA+, Early RA: Results from a Post Hoc Analysis of the AVERT-2 Study by Baseline Erosion Scores
- Abstract Number: 0768
Reevaluating Clinical Outcomes of Patients on Combination Biologics
- Abstract Number: 1567
Refractory Macular Edema Due to Behçet’s Disease. Multicenter Comparative Study of Adalimumab and Certolizumab Pegol
- Abstract Number: 0618
Regulation of IgA Secretion Through PAD2-mediated Citrullination of MZB1
- Abstract Number: 0867
Regulatory Haplotype of CXCR4 Is Associated with sJIA and Corelates with Enhanced Neutrophil and CD14+ Monocyte Migration
- Abstract Number: 0989
Regulatory T Cell Defects in SLE and Therapy with a Novel IL-2 Mutein: Phase 1 Clinical Results with Efavaleukin Alfa
- Abstract Number: 0841
Relation of PainDETECT to Unpredictable Pain in People with or at Risk of Knee Osteoarthritis
- Abstract Number: 1873
Relationship Between Baseline Characteristics of Rheumatoid Arthritis and Types of Mortality: Study of Cohort Followed Prospectively
- Abstract Number: 1401
Relationship Between Disease Activity and Adverse Events of Interest in Patients with RA on Tofacitinib or TNF Inhibitors: Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study
- Abstract Number: 0787
Relationship Between Humoral and Cellular Immune Responses in Persons with Rheumatoid Arthritis Following a Third Dose of COVID-19 Vaccine
- Abstract Number: 1355
Relationships Between Work Productivity, Activity Impairment, and Select Patient-Reported Outcomes in Patients with Ankylosing Spondylitis: A Post Hoc Analysis of Two Placebo-Controlled Trials
- Abstract Number: 2258
Relative Frequencies of the Spectrum of MRI Lesions in the Sacroiliac Joints of Healthy Individuals and Patients with Non-Specific Back Pain: What Is the Impact of Increasing Age?
- Abstract Number: 1232
Reliability and Validity of Single Axial Slice vs. Multiple Slice Quantitative Measurement of the Volume of Effusion-Synovitis on 3T Knee MRI in Knees with Osteoarthritis
- Abstract Number: 0811
Reliability of CRP as an Inflammatory Marker in Patients with Immune Mediated Inflammatory Diseases (IMIDs) and Liver Dysfunction
- Abstract Number: 2200
Reliability of Medication Information Derived from EHR Data Compared to Insurance Claims: An Analysis of Biologic Medications in RISE and Medicare
- Abstract Number: 0853
Reliability of MRI Lesions Comprising the Preliminary OMERACT Juvenile Idiopathic Arthritis MRI Score (OMERACT JAMRI-SIJ): What Is the Impact of Systematic Reader Calibration?
- Abstract Number: 1301
Reliable Transition Policy Distribution and Transition Readiness Assessment Questionnaire Completion Using a Digital Intervention in a Pediatric Rheumatology Clinic
- Abstract Number: 1113
Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study
- Abstract Number: 2086
Remission and Low Disease Activity Are Associated with Lower Health Care Costs in an International Inception Cohort of Patients with Systemic Lupus Erythematosus
- Abstract Number: PP07
Remissions and Vigilance
- Abstract Number: 0758
Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE)-like Syndrome After Immune Checkpoint Inhibition: A CanRIO Study
- Abstract Number: 0731
Remote Monitoring of Chronic Inflammatory Musculoskeletal Diseases– Results of the Digireuma Feasibility Study
- Abstract Number: 1069
Renal Involvement Other Than Renal Crisis in Systemic Sclerosis: A Retrospective Monocentric Cohort Study
- Abstract Number: 0514
Renal Response Outcomes of North American Youth with Proliferative Lupus Nephritis Treated with the EuroLupus versus NIH Cyclophosphamide Dosing Regimen
- Abstract Number: 1543
Resolution of PMR Signs and Symptoms in Patients Treated with Sarilumab: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR) in Relapsing PMR
- Abstract Number: 1314
Response Rates for Lumbar Spine, Total Hip, and Femoral Neck Bone Mineral Density with Abaloparatide in Men: Results from the ATOM Study
- Abstract Number: 1026
Responsiveness and Minimal Clinically Important Difference in Patient-Reported Outcome Measures Among Patients with Psoriatic Arthritis
- Abstract Number: 0851
Responsiveness of Patient-Reported Physical Function Measures in Juvenile Arthritis
- Abstract Number: 2069
Responsiveness of the Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Test (CAT) Measures in a Single Canadian Lupus Cohort
- Abstract Number: 0589
Restoration of NAD+ Levels in Rheumatoid Arthritis with NAD+ Boosters as a Novel Therapeutic Strategy to Resolve Acute Inflammation
- Abstract Number: 0103
Retention in Rheumatology Care and Receipt of Lupus-Specific Serologic Testing Among Young Adults with Systemic Lupus Erythematosus: A Medicare Cohort Study
- Abstract Number: 0920
Retention Rate and Safety of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients with Rheumatoid Arthritis Associated with Interstitial Lung Disease: Results from the KOBIO Registry
- Abstract Number: 0133
Retention Rate of Targeted Therapies in Erdheim-Chester Disease
- Abstract Number: 1434
Retrospective Analysis of Tocilizumab-induced Neutropenia in Patients with Rheumatoid Arthritis
- Abstract Number: 0927
Review of 167,990 Same Day RAPID3, CDAI Scores for 61,312 Patients Receiving DMARD Treatment for Rheumatoid Arthritis; Evaluations of Disease Assessments and Treatment Discontinuation
- Abstract Number: 0061
Rheumatic Diagnostic Code Trajectories for Patients with RA and SLE in a U.S. Rheumatology Registry
- Abstract Number: 0805
Rheumatic Fever and Streptococcal Cutaneous Infection: A Case-control Study in the Loyalty Islands, New Caledonia
- Abstract Number: 0756
Rheumatic Toxicities of Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and the Effect of Pre-existing Autoimmune and Non-immune Mediated Rheumatic Conditions
- Abstract Number: 1668
Rheumatic Toxicities of Immune Checkpoint Inhibitors Predict Favourable Tumour Responses in Patients with Advanced Melanoma
- Abstract Number: 0077
Rheumatoid Arthritis – Are We Getting to Target?
- Abstract Number: 0891
Rheumatoid Arthritis and the Rheumatic Disease Comorbidity Index (RDCI): Its Impact on Disease Activity
- Abstract Number: 0247
Rheumatoid Arthritis as a Modifier of the Cognition-Daily Function Association
- Abstract Number: 0258
Rheumatoid Arthritis Associated Interstitial Lung Disease Across Continents
- Abstract Number: 0910
Rheumatoid Arthritis Associated Interstitial Lung Disease: The Role of Non-Criteria Autoantibodies
- Abstract Number: 2007
Rheumatoid Arthritis Associated Lymphoproliferative Disorders: Current Features and It’s Changing Pattern Due to the Influence of Anti-rheumatic Drugs
- Abstract Number: 0121
Rheumatoid Arthritis Care Experiences of Black People Living in Canada: A Qualitative Study to Inform Treatment Guidelines
- Abstract Number: 0065
Rheumatoid Arthritis Clinical Care Pathway Implementation: A Step Towards Improved Outcomes and Value-Based Care
- Abstract Number: 2246
Rheumatoid Arthritis Patient Discordance with Provider Treatment Goals Is Associated with Poorer RA Outcomes
- Abstract Number: 0045
Rheumatoid Arthritis Patient-derived Anti-citrullinated Protein Antibodies (ACPAs) Ameliorate Joint Inflammation in Early Collagen-antibody Induced Arthritis (CAIA)
- Abstract Number: 0304
Rheumatoid Arthritis Patients Who Switched Treatment from Adalimumab to Upadacitinib Demonstrate a Robust Reduction of Inflammation-related Biomarkers: Proteomics Analysis from the SELECT-COMPARE Phase 3 Study
- Abstract Number: 0623
Rheumatoid Synovial Fibroblasts Display Imprinted Memory of Their Synovial Endotype Which Can Be Plastically Modulated by B-cells Crosstalk
- Abstract Number: 0737
Rheumatologic Rashes in Different Skin Types and Confidence in Diagnosis Among Internal Medicine Residents in a New York City Hospital
- Abstract Number: 1255
Rheumatologists Overcall Sacroiliitis on X-ray and MRI in Axial Spondyloarthritis Patients: Data from the BelGian Inflammatory Arthritis and SpoNdylitis cohorT (Be-GIANT)
- Abstract Number: 0239
Rheumatology Fellowship Programs – What Are Our Missions and What Are We Missing? A Mixed Methods Analysis of Publically-Available Mission Statements from the 126 Adult Rheumatology Fellowships in the United States
- Abstract Number: 2173
Rheumatology Telemedicine Consults: Impact of Demographic Variability on Patient Perception in Systemic Sclerosis versus Rheumatoid Arthritis Pts
- Abstract Number: 0232
RheumMadness: Early Learner Experience and Impact
- Abstract Number: 1981
Rho-GTPase Expression Recruits CD14+ Cells to Joints in Rheumatoid Arthritis and Predicts Good Response to JAK-inhibitor Treatment
- Abstract Number: 0308
Risankizumab (RZB) Demonstrates Long-Term Efficacy Across Subgroups in Patients with Active Psoriatic Arthritis (PsA): A Post Hoc, Integrated Analysis from the Phase 3 (KEEPsAKE 1 and KEEPsAKE 2) Studies
- Abstract Number: 0710
Risk Factors Associated with COVID-19 Breakthrough Infection Among Patients with Systemic Autoimmune Rheumatic Diseases: A Cohort Study
- Abstract Number: 1469
Risk Factors for Herpes Zoster Among Patients with Systemic Lupus Erythematosus
- Abstract Number: 1524
Risk Factors for Lung Function Decline in Systemic Sclerosis Interstitial Lung Disease in a Large Single-Center Cohort
- Abstract Number: 1207
Risk Factors for Major Cardiovascular Events (MACE) in Inflammatory Arthritis: A Time-dependent Analysis on the Inflammatory Burden, Use of DMARDs, NSAIDs, and Steroid
- Abstract Number: 1331
Risk Factors for Osteoporotic Fracture in Women with Established Long-Term Rheumatoid Arthritis
- Abstract Number: 2196
Risk Factors for Severe COVID-19 Outcomes: A Study of Immune-mediated Inflammatory Diseases, Immunomodulatory Medications, Vaccination Status, and Comorbidities in a Large US Healthcare System
- Abstract Number: 0494
Risk for Visual Loss in Patients with Giant Cell Arteritis
- Abstract Number: 0898
Risk of Aortic Stenosis and Undergoing Aortic Valve Replacement in Rheumatoid Arthritis: An Underrecognized Cardiovascular Complication
- Abstract Number: 2075
Risk of Bloodstream Infection in Patients with Systemic Lupus Erythematosus Exposed to Prolonged Moderate to High Dose Glucocorticoids
- Abstract Number: L06
Risk of Extended Major Adverse Cardiovascular Event Endpoints with Tofacitinib vs TNF Inhibitors in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study
- Abstract Number: 1396
Risk of Hospitalized Infections in Older Elderly Rheumatoid Arthritis Patients Treated with Biological/Targeted Synthetic DMARDs: Evaluation Using Data from a Japanese Claims Database
- Abstract Number: 0302
Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis
- Abstract Number: 0723
Risk of Major Adverse Cardiovascular and Venous Thromboembolism Events in Patients with Rheumatoid Arthritis Exposed to JAK Inhibitors versus Adalimumab: A Nationwide Cohort Study
- Abstract Number: 1033
Risk of Mood Disorders in SpA Patients and Correlations with Disease Activity, Quality of Life and Working Ability: Analysis of a Monocentric Cohort
- Abstract Number: 1648
Risk of Vascular Events Under the Treatments with Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: An Analysis Using Japanese Health Insurance Database
- Abstract Number: 1049
Risk Stratification of Patients with Systemic Sclerosis-associated Pulmonary Arterial Hypertension in EUSTAR Using the Current and New Proposed Criteria
- Abstract Number: 0720
Risk-Benefit Assessment of Primary Prophylaxis for Pneumocystis Pneumonia in Patents with Rheumatic Diseases Exposed to Rituximab: A Multicenter Cohort Study
- Abstract Number: 0268
Risks of Mortality in Elderly-onset Rheumatoid Arthritis: Analysis from the TRA Clinical Electronic Registry
- Abstract Number: 1520
Rituximab and Tocilizumab and Their Effect on Lung Disease Progression in Scleroderma. a Retrospective Cohort Study at a Single Centre
- Abstract Number: 0527
Rituximab as Maintenance Therapy for ANCA-associated Vasculitides: Pooled Analysis and Long-term Outcome of MAINRITSAN Trials
- Abstract Number: 0147
Rituximab in IgG4-Related Diseae: An Open-Label Non-Randomized Observational Study
- Abstract Number: 0781
Rituximab Treated Patients with Hypogammaglobulinemia Are Less Likely to Seroconvert Following SARS-CoV-2 Vaccine Supplemental Dose
- Abstract Number: 1084
Rituximab versus Cyclophosphamide for Induction Therapy in Granulomatosis with Polyangiitis: A Target Trial Emulation Study
- Abstract Number: 0003
Rituximab versus Cyclophosphamide for the Treatment of Connective Tissue Disease Associated Interstitial Lung Disease (RECITAL): A Sub-group Analysis of a Multi-centre Randomised Controlled Trial
- Abstract Number: 0931
Rituximab versus Leflunomide in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis Despite Methotrexate Treatment- an Open Label Randomized Controlled Trial
- Abstract Number: 0762
Rituximab-treated Rheumatic Patients: B-cell Levels Predict Sero-conversion After COVID-19 Boost or Re-vaccination in Initial Vaccine Non-responders
- Abstract Number: 2096
Role of Cell-Bound Complement Fragments as Biomarkers to Determine Disease Activity in Patients with Systemic Lupus Erythematosus
- Abstract Number: 1709
Role of Corneal Langerhans Dendritic Cells in Lupus Keratitis
- Abstract Number: 0482
Role of miR-146a and miR-146b in Giant Cell Arteritis
- Abstract Number: 1442
Role of Platelet-bound Complement Activation Product (PC4d) in Predicting Risk of Future Thrombotic Events in Systemic Lupus Erythematosus
- Abstract Number: 0012
Role of Type L IFN Signaling on B Cell Pathogenicity in Early Sjögren’s Disease in Mouse Model
- Abstract Number: L11
Romosozumab versus Denosumab in High-risk Patients with Glucocorticoid-induced Osteoporosis: A Pilot Randomized Controlled Trial
ACR Convergence 2022
November 10-14, 2022. Philadelphia, PA.